Evidence map›Paper›PMID 32620905›Full record

ArticleNature communications2020

The ataxin-1 interactome reveals direct connection with multiple disrupted nuclear transport pathways.

Sunyuan Zhang, Nicholas A Williamson, Lisa Duvick, Alexander Lee, Harry T Orr, Austin Korlin-Downs, Praseuth Yang, Yee-Foong Mok, David A Jans, Marie A Bogoyevitch

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. RANBP17 Overexpression Restores Nucleocytoplasmic Transport and Ameliorates Neurodevelopment in Induced DYT1 Dystonia Motor Neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  10. Nuclear transport proteins: structure, function, and disease relevance.Signal transduction and targeted therapy · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Sunyuan ZhangDepartment of Biochemistry and Molecular Biology, University of Melbourne, Parkville, VIC, 3010, Australia.
Nicholas A WilliamsonBio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC, 3010, Australia.ORCID http://orcid.org/0000-0002-2173-3452
Lisa DuvickInstitute of Translational Neuroscience, and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, 55455, USA.
Alexander LeeNuclear Signalling Lab., Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, 3800, Australia.
Harry T OrrInstitute of Translational Neuroscience, and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, 55455, USA.
Austin Korlin-DownsInstitute of Translational Neuroscience, and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, 55455, USA.
Praseuth YangInstitute of Translational Neuroscience, and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, 55455, USA.
Yee-Foong MokBio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC, 3010, Australia.
David A JansNuclear Signalling Lab., Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, 3800, Australia. david.jans@monash.edu.ORCID http://orcid.org/0000-0001-5115-4745
Marie A BogoyevitchDepartment of Biochemistry and Molecular Biology, University of Melbourne, Parkville, VIC, 3010, Australia.
The University of Melbourne · AUUniversity of Minnesota · USMonash University · AU

Funding

Molecular Genetics of the SCA1 LocusR37NS022920 · NINDS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI ORR, HARRY T. · 2004 to 2017
$5.9M
MOLECULAR GENETICS OF THE SCA1 LOCUS ON CHROMOSOME 6PR01NS022920 · NINDS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI ORR, HARRY T. · 1986 to 2022
$3.2M
NINDS NIH HHS R01 NS022920NINDS NIH HHS R37 NS022920
6 · The paper itself

Abstract

The expanded polyglutamine (polyQ) tract form of ataxin-1 drives disease progression in spinocerebellar ataxia type 1 (SCA1). Although known to form distinctive intranuclear bodies, the cellular pathways and processes that polyQ-ataxin-1 influences remain poorly understood. Here we identify the direct and proximal partners constituting the interactome of ataxin-1[85Q] in Neuro-2a cells, pathways analyses indicating a significant enrichment of essential nuclear transporters, pointing to disruptions in nuclear transport processes in the presence of elevated levels of ataxin-1. Our direct assessments of nuclear transporters and their cargoes confirm these observations, revealing disrupted trafficking often with relocalisation of transporters and/or cargoes to ataxin-1[85Q] nuclear bodies. Analogous changes in importin-β1, nucleoporin 98 and nucleoporin 62 nuclear rim staining are observed in Purkinje cells of ATXN1[82Q] mice. The results highlight a disruption of multiple essential nuclear protein trafficking pathways by polyQ-ataxin-1, a key contribution to furthering understanding of pathogenic mechanisms initiated by polyQ tract proteins.

Indexed as

Active Transport, Cell NucleusAnimalsAtaxin-1Cell Line, TumorCell NucleusDisease Models, AnimalHeLa CellsHumansMiceMutationNuclear Pore Complex ProteinsNucleocytoplasmic Transport ProteinsPeptidesProtein BindingPurkinje CellsSpinocerebellar AtaxiasAtaxin-1nuclear pore complex protein 98Nuclear Pore Complex ProteinsNucleocytoplasmic Transport ProteinsNUP62 protein, mousePeptidespolyglutamine

Identifiers

PMID32620905
PMCPMC7334205
OpenAlexW3039566069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.